Zolpidem Action During Prolonged Disorders of Consciousness (Case Report)

The paper describes two patients with prolonged disorders of consciousness (PDC) because of non-traumatic brain injury, in whom a clear neurodynamic response to Zolpidem was observed.
In order to illustrate systemic cerebral responses to administration of this drug in LIC patients, an analysis of clinical and electrophysiological changes has been undertaken.
It has been shown that the result of Zolpidem applications in patients with prolonged disorders of consciousness (PDC) should be assessed not only by consciousness dynamics, but with the help of electroencephalogram (EEG) monitoring, too. Distinct response to Zolpidem during different periods of recovery in one patients was found.
Zolpidem can render various effects in patients in vegetative state/with unresponsive wakefulness syndrome (VS/UWS) and in minimally conscious state (MCS). In one patient, sedation with EEG activation was observed, which was a sign of favorable prognosis. The other patient developed more than once local convulsions after Zolpidem administration followed by contact augmentation on the next day.
The mechanism of action, necessary doses of drugs, and markers of forecasting the successful effect of that drug are yet to be further studied.

1. Golubev A.M., Kuzovlev A.N., Antonova V.V., Zakharchenko V.E., Petrova M.V., Grechko A.V. Molecular Biomarkers for Prediction of Neurological Outcome after Sudden Circulatory Arrest (Review). Obschaya Reanimatologiya=General Reanimatology. 2018; 14 (3): 68–81. [In Russ.] DOI: 10.15360/1813-9779-2018-3-68-81

2. Schnakers C., Laureys S. «Coma and Disorders of Consciousness» Second Edition, Springer, 2018.

3. Clauss R.P., Guldenpfenning W.N., Nel H.W., Sathekge M.M., Venkannagari RR. Extraordinary arousal from semi-comatose state on Zolpidem. A case report. South African Medical Journal. 2000; 90 (1): 68–72. PMID: 10721397

4. Bomalaski M.N., Claflin E.S., Townsend W., Peterson M.D. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. JAMA Neurol. 2017; 74 (9): 1130–1139. DOI: 10.1001/jamaneurol.2017.1133.

5. Kondrateva E.A. Vegetative condition: etiology, pathogenesis, diagnosis and treatment / E.A. Kondrateva I.V. Yakovenko. – Meditsina: 2014. – 361 p.: col.ill., tab.; 2, ISBN978-5-225-10023-0. [In Russ.]

6. Brefel-Courbon C., Payoux P., Sommet A., Slaoui T., Raboyeau G., Lemesle B., Puel M, Montastruc JL, Demonet JF, Cardebat D. Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy. Ann Neurol. 2007; 62 (1): 102–105 DOI: 10.1002/ana.21110

7. Noormandi A., Shahrokhi M., Khalili H. Potential benefits of zolpidem in disorders of consciousness. Expert Rev Clin Pharmacol. 2017; 10 (9): 983–992. DOI: 10.1080/17512433.2017.1347502

8. Bomalaski M.N., Smith S.R.Improved Arousal and Motor Function Using Zolpidem in a Patient With Space-Occupying Intracranial Lesions: A Case Report. PM R. 2017; 9 (8): 831–833. DOI: 10.1016/j.pmrj.2016.12.011.

9. Appu M., Noetzel M. Clinically significant response to zolpidem in disorders of conscious- ness secondary to anti-N-methyl-D-aspartate receptor encephalitis in a teenager: a case report. Pediatr Neurol. 2014; 50 (3): 262–264. DOI: 10.1016/j.pediatrneurol.2013.11.001

10. Mochalova E.G., Legostaeva L.A., Zimin A.A., Yusupova D.G., Sergeev D.V., Ryabinkina Yu.V., Bodin E., Suponeva N. A., Piradov M.A. The Russian version of the revised coma recovery scale is a standardized method for assessing patients with chronic impaired. Zhurnal nevrologii i psihiatrii im S.S. Korsakova, Specvypuski. 2018; 118 (3): 25–31. DOI: 10.17116/jnevro20181183225-31. [In Russ.]

11. Hagen C., Malkmus D., Durham P. Levels of cognitive functioning. Downey: Rancho Los Amigos Hospital Inc.; 1987

12. Lo Y., Tan E., Ratnagopal P., Chan L., Tan T. Zolpidem and its effects on hypoxic encephalopathy. Ann Neurol. 2008; 64 (4): 477–478. DOI: 10.1016/j.clp.2009.07.011

13. Tucker C., Sandhu K. The Effectiveness of Zolpidem for the Treatment of Disorders of Consciousness. Neurocrit Care. 2016; 24 (3): 488–493. DOI: 10.1007/s12028-015-0227-5.

14. Du B., Shan A., Zhang Y., Zhong X., Chen D., Cai K. Zolpidem arouses patients in vegetative state after brain injury: quantitative evaluation and indications. Am J Med Sci. 2014; 347 (3): 178–82. DOI: 10.1097/MAJ.0b013e318287c79c

15. Whyte J., Rajan R., Rosenbaum A., Katz D., Kalmar K., Seel R., Greenwald B., Zafonte R., Demarest D., Brunner R., Kaelin D.. Zolpidem and restoration of consciousness. Am J Phys Med Rehabil. 2014; 93 (2): 101–113. DOI: 10.1097/PHM.0000000000000069

16. Hofmeijer J., van Putten M.J. EEG in postanoxic coma: Prognostic and diagnostic value. Clin Neurophysiol. 2016 Apr; 127 (4): 2047–2055. DOI: 10.1016/j.clinph.2016.02.002.

17. Machado C., Estevez M., Rodriguez R., Perez-Nellar J., Chinchilla M., DeFina P., Leisman G., Carrick F.R., Melillo R., Schiavi A., Gutierrez J., Carballo M., Machado A., Olivares A., Perez-Cruz N. Zolpidem arousing effect in persistent vegetative state patients: autonomic, EEG and behavioral assessment. Curr Pharm Des. 2014; 20 (26): 4185–4202. PMID: 24025063

18. Thonnard M., Gosseries O., Demertzi A., Lugo Z., Vanhaudenhuyse A., Bruno M., Chatelle C., Thibaut T., Charland-Verville V., Habbal D., Schnakers C., Laureys S. Effect of zolpidem in chronic disorders of consciousness: a prospective open label study. Funct Neurol. 2013; 28 (4): 259–264. DOI: 10.11138/FNeur/2013.28.4.259

19. Du B., Shan A., Zhang Y., Zhong X., Chen D., Cai K. Zolpidem arouses patients in vegetative state after brain injury: quantitative evaluation and indications. Am J Med Sci. 2014; 347 (3): 178–182. DOI: 10.1097/MAJ.0b013e318287c79c

20. Cohen L., Chaaban B., Habert M.O. Transient improvement of aphasia with zolpidem. N Engl J Med. 2004; 350 (9): 949–950. DOI: 10.1056/NEJM200402263500922

21. Rodriguez-Rojas R., Machado C., Alvarez L., Carballo M., Estevez M., Perez-Nellar J., Pavon N., Chinchilla M., Carrick F.R., DeFina P.. Zolpidem induces paradoxical metabolic and vascular changes in a patient with PVS. Brain Inj. 2013; 27 (11): 1320–1329. DOI: 10.3109/02699052.2013.794961

22. Chatelle C., Thibaut A., Gosseries O., Bruno M.A., Demertzi A., Bernard C, Hustinx R, Tshibanda L, Bahri MA, Laureys S. Changes in cerebral metabolism in patients with a minimally conscious state responding to zolpidem. Front Hum Neurosci. 2014; 8: 917. DOI: 10.3389/fnhum.2014.00917

23. Williams S.T., Conte M.M., Goldne A.M., Noirhomme Q., Gosseries O., Thonnard M., Beattie B., Hersh J., Katz D., Victor J.D., Laureys S., Schiff N.D. Common resting brain dynamics indicate a possible mechanism underlying zolpidem response in severe brain injury. Elife. 2013; 2: e01157. DOI: 10.1016/j.conb.2014.09.008.

24. Calabro R.S., Arico I., De Salvo S., Conti-Nibali V., Bramanti P. Transient awakening from vegetative state: is high-dose zolpidem more effective? Psychiatry Clin Neurosci. 2015; 69 (2): 122–123. DOI: 10.1111/pcn.12215

25. Clauss R.P., Nel W.H. Effect of zolpidem on brain injury and diaschisis as detected by 99mTc HMPAO brain SPECT in humans. Arzneimittelforschung. 2004; 54 (10): 641–646. DOI: 10.1055/s-0031-1297015

26. Sutton J.A., Clauss R.P. A review of the evidence of zolpidem efficacy in neurological disability after brain damage due to stroke, trauma and hypoxia: A justification of further clinical trials. Brain Inj. 2017; 31 (8): 1019–1027. DOI: 10.1080/02699052.2017.1300836.

27. Schiff N.D. Central thalamic deep brain stimulation to support anterior forebrain mesocircuit function in the severely injured brain. Journal of Neural Transmission (Vienna, Austria: 1996). PMID 27113938.

28. Delargy M., O’Connor R., McCann A., Galligan I., Cronin H., O’Toole D.G., O’Toole C. An analysis of the effects of using Zolpidem and an innovative multimodal interdisciplinary team approach in prolonged disorders of consciousness (PDOC), Brain Injury,2019; 33: 2, 242-248 DOI: 10.1080/02699052.2018.1537008.

29. Thibaut A., Schiff N., Giacino J., Laureys S., Gosseries O. Therapeutic interventions in patients with prolonged disorders of consciousness. The Lancet Neurology. 2019; 18. 10.1016/S1474-4422 (19)30031-6. DOI: 10.1016/S1474-4422 (19)30031-6.

30. Patent for invention No. 2697230 «A method for predicting recovery of consciousness in patients in a vegetative state of non-traumatic genesis based on an analysis of the dynamics of the background bioelectric activity of the brain after applying zolpidem» from 19.11. 2018 Kondratieva E.A., Sinkin M.V., Borovikova V.N., Ulitin A.Yu. [In Russ.]